ImmuPharma PLC (AIM:IMM) says a broad group of potential partners, including several of the world’s ten largest pharmaceutical companies, has entered discussions over its P140 autoimmune programme.
The company added that a number of these parties have already signed confidentiality agreements, allowing deeper technical and commercial reviews to begin.
Talks span scientific, manufacturing and business considerations. That is common in partnership negotiations, which typically involve lengthy due diligence work and detailed review of clinical data before any formal proposals are made.
ImmuPharma said its goal is to secure “the best fit” partner for advancing and commercialising P140, a treatment it believes represents a new approach to diagnosing and treating autoimmune conditions.
The company had previously aimed to complete a deal by the end of 2025. After assessing the state of discussions, the board now expects the timeline to slip, with completion targeted for as soon as practicable in 2026.
ImmuPharma said it will update the market as talks progress.
Tim McCarthy, the chief executive, said: “We are very encouraged by the positive response we have received in our partnering discussions…
"The whole team is dedicated to securing a partnership deal that does justice to the innovation and clinical potential of P140, valuing a more methodical approach over speed, so the best outcome for shareholders can be achieved.”
Alongside the partnership update, the company reported a stronger financial position.
Recent research and development tax credits, the exercise of share warrants earlier in the year and additional proceeds from its funding arrangement with Lanstead Capital have taken total receipts from that deal to about £2 million, slightly above the original £1.875 million subscription value.
As a result, ImmuPharma now has sufficient cash to operate well into the final quarter of 2026 and reiterated that it has no plans to raise new funds.